Chemical carcinogenesis

Toxicological Sciences

Volumn 120, Issue SUPPL.1, 2011, Pages

  Cohen, Samuel M ^a,b   Arnold, Lora L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Carcinogenicity testing; Cell proliferation; DNA reactivity; Human relevance; Non DNA reactivity

Indexed keywords

CARCINOGEN; CHEMICAL COMPOUND; DNA;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGEN DNA INTERACTION; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; CELL REGENERATION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; DECISION MAKING; DNA ADDUCT; DNA REPAIR; GENOMICS; GENOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; METABOLIC ACTIVATION; METABOLISM; NONHUMAN; SCREENING; TOXICITY TESTING;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; CELL PROLIFERATION; CHEMOPREVENTION; DNA; DNA DAMAGE; HUMANS; MUTAGENICITY TESTS; MUTAGENS; NEOPLASMS; RISK FACTORS;

ANIMALIA;

EID: 79952097411     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq365     Document Type: Article

References (122)

1. Alden, C. L., Smith, P. F., Piper, C. E., and Brej, L. (1996). A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol. Pathol. 24, 722-725.
2. Ames, B. N., Durston, W. E., Yamasaki, E., and Lee, F. D. (1973). Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. U.S.A. 70, 2281-2285.
3. Andersen, M., Brusick, D., Cohen, S., Dragan, Y., Frederick, C., Goodman, J. I., Hard, G., Meek, B., and O'Flaherty, E. J. (1998). U.S. Environmental Protection Agency's revised cancer guidelines for carcinogen risk assessment. Toxicol. Appl. Pharmacol. 153, 133-136.
4. Armitage, P., and Doll, R. (1954). The age distribution of cancer and a multistage theory of carcinogenesis. Br. J. Cancer 8, 1-12.
5. Baldwin, R. W. (1973). Immunological aspects of chemical carcinogenesis. Adv. Cancer Res. 18, 1-75.
6. Berenblum, I., and Shubik, P. (1947). A new quantitative approach to the study of stages of carcinogenesis in the mouse's skin. Br. J. Cancer 1, 383-391.
7. Boddy, A. V., and Ratain, M. J. (1997). Pharmacogenetics in cancer etiology and chemotherapy. Clin. Cancer Res. 3, 1025-1030.
8. Boobis, A. R., Cohen, S. M., Dellarco, V., McGregor, D., Meek, M. E., Vickers, C., Willcocks, D., and Farland, W. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 36, 781-792.
9. Boobis, A. R., Doe, J. E., Heinrich-Hirsch, B., Meek, M. E., Munn, S., Ruchirawat, M., Schlatter, J., Seed, J., and Vickers, C. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit. Rev. Toxicol. 38, 87-96.
10. Boutwell, R. K. (1964). Some biological aspects of skin carcinogenesis. Progr. Exp. Tumor Res. 4, 207-250.
11. Boveri, T. (1914). In Zur Frage der Enstehung Maligner Tumoren. Verlag von Gustav Fischer, Jena, Germany.
12. Bryan, G. T. (1969). Role of tryptophan metabolites in urinary bladder cancer. Am. Ind. Hyg. Assoc. J. 30, 27-34.
13. Burnet, M. F. (1957). Cancer-a biological approach. IV. Practical applications. Br. Med. J. 1, 844-847.
14. Burnet, M. F. (1964). Immunologic factors in the process of carcinogenesis. Br. Med. Bull. 20, 154-158.
15. Calabrese, E. J. (2009). The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. Arch. Toxicol. 83, 203-225.
16. Capen, C. C. (1998). Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system. Toxicol. Lett. 102, 405-409.
17. Carmichael, N. G., Barton, H. A., Boobis, A. R., Cooper, R. L., Dellarco, V. L., Doerrer, N. G., Fenner-Crisp, P. A., Doe, J. E., Lamb, I. V., JC., et al. (2006). Agricultural chemical safety assessment: a multisector approach to the modernization of human safety requirements. Crit. Rev. Toxicol. 36, 1-7.
18. Cavalieri, E. L., Li, K. M., Balu, N., Saeed, M., Devanesan, P., Higginbotham, S., Zhao, J., Gross, M. L., and Rogan, E. G. (2002). Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23, 1071-1077.
19. Chapman, J. R., Webster, A. C., Kaldor, J. M., and Grulich, A. E. (2006). Cancer incidence before and after kidney transplantation. JAMA 296, 2823-2831.
20. Chuang, S. C., La Vecchia, C., and Boffetta, P. (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 286, 9-14.
21. Clayson, D. B., and Cooper, E. H. (1970). Cancer of the urinary tract. In Advances in Cancer Research. (G. Klein and S. Weinhouse, Eds.), Vol. 13, pp. 271-381. Academic Press, Inc., New York, NY.
22. Cleaver, J. E., Charles, W. C., McDowell, M. L., Sadinski, W. J., and Mitchell, D. L. (1975). Overexpression of the XPA repair gene increases resistance to ultraviolet radiation in human cells by selective repair of DNA damage. Cancer Res. 55, 6152-6160.
23. Cohen, S. M. (1991). Analysis of modifying factors in chemical carcinogenesis. In Modification of Tumor Development of Rodents, Progress in Experimental Tumor Research. (N. Ito, Ed.), Vol. 33, pp. 21-40. Karger and Basel, New York, NY.
24. Cohen, S. M. (1998a). Cell proliferation and carcinogenesis. Drug Metab. Rev. 30, 339-357.
25. Cohen, S. M. (1998b). Cell proliferation in the evaluation of carcinogenic risk and the inadequacies of the initiation-promotion model. Int. J. Toxicol. 17, 129-142.
26. Cohen, S. M. (1999a). Calcium phosphate-containing urinary precipitate in rat urinary bladder carcinogenesis. International Agency for Research on Cancer. IARC Sci. Publ. 147, 175-189.
27. Cohen, S. M. (1999b). Infection, cell proliferation, and malignancy. In Microbes and Malignancy: Infection as a Cause of Cancer. (J. Parsonnet and S. Horning, Eds.), pp. 89-106. Oxford University Press, New York, NY.
28. Cohen, S. M. (2004). Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol. Sci. 80, 225-229.
29. Cohen, S. M. (2010). Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two year bioassay is no longer necessary. Toxicol. Pathol. 38, 487-501.
30. Cohen, S. M., Arnold, L. L., Cano, M., Ito, M., Garland, E. M., and Shaw, R. A. (2000). Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. Carcinogenesis 21, 783-792.
31. Cohen, S. M., Arnold, L. L., and Emerson, J. L. (2008). Safety of saccharin. Agro Food Ind. Hi-Tech. 19, 26-29.
32. Cohen, S. M., Boobis, A. R., Meek, M. E., Preston, R. J., and McGregor, D. B. (2006). 4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS human relevance framework for analysis of a cancer mode of action for humans. Crit. Rev. Toxicol. 36, 803-819.
33. Cohen, S. M., and Ellwein, L. B. (1990a). Cell proliferation in carcinogenesis. Science 249, 1007-1011.
34. 01 study. Toxicol. Appl. Pharmacol. 104, 79-93.
35. Cohen, S. M., and Ellwein, L. B. (1991). Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51, 6493-6505.
36. Cohen, S. M., Purtilo, D. T., and Ellwein, L. B. (1991). Pivotal role of increased cell proliferation in human carcinogenesis. Modern Pathol. 4, 371-382.
37. Cohen, S. M., Robinson, D., and MacDonald, J. (2001). Alternative models for carcinogenicity testing. Toxicol. Sci. 64, 14-19.
38. Cooper, E. H., Frank, G. L., and Wright, D. H. (1966). Cell proliferation in Burkitt tumours. Eur. J. Cancer 2, 377-384.
39. Creech, J., Jr., and Johnson, M. (1974). Angiosarcoma of liver in the manufacture of polyvinyl chloride. J. Occup. Med. 16, 150-151.
40. DeBaun, J. R., Miller, E. C., and Miller, J. A. (1970). N-Hydroxy-2-acetylaminofluorene sulfotransferase: its probable role in carcinogenesis and in protein(methion-S-yl) binding in rat liver. Cancer Res. 30, 577-595.
41. Doe, J. E., Boobis, A. R., Blacker, A., Dellarco, V., Doerrer, N. G., Franklin, C., Goodman, J. I., Kronenberg, J. M., Lewis, R., McConnell, E. E., et al. (2006). A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. Crit. Rev. Toxicol. 36, 37-69.
42. Dragan, Y. P., Sargent, L., Xu, Y. D., Xu, Y. H., and Pitot, H. C. (1993). The initiation-promotion-progression model of rat hepatocarcinogenesis. Proc Soc. Exp. Biol. Med. 202, 16-24.
43. Ellinger-Ziegelbauer, H., Gmuender, H., Bandenburg, A., and Ahr, H. J. (2008). Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637, 23-39.
44. Gallo, M. A. (2008). History and scope of toxicology. In Toxicology. The Basic Science of Poisons, 7th ed. (C. D. Klaassen, Ed.), pp. 3-10., McGraw Hill Medical, New York, NY.
45. Gee, P., Maron, D. M., and Ames, B. N. (1994). Detection and classification of mutagens: a set of base-specific Salmonella tester strains. Proc. Natl. Acad. Sci. U.S.A. 91, 11606-11610.
46. Gonzalez, F. J., and Shah, Y. M. (2008). PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246, 2-8.
47. Good, R. A. (1968). Experiments of nature in immunobiology. N. Engl. J. Med. 279, 1344-1345.
48. Greenfield, R. E., Ellwein, L. B., and Cohen, S. M. (1984). A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. Carcinogenesis 5, 437-445.
49. Grulich, A. E., van Leeuwen, M. T., Falster, M. O., and Vajdic, C. M. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosup-pressed transplant recipients: a meta-analysis. Lancet 370, 59-67.
50. Guan, N., Fan, Q., Ding, J., Zhao, Y., Lu, J., Ai, Y., Xu, G., Zhu, S., Yao, C., Jiang, L., et al. (2009). Melamine-contaminated powdered formula and urolithiasis in young children. N. Engl. J. Med. 360, 1067-1074.
51. Guengerich, F. P. (2000). Metabolism of chemical carcinogens. Carcinogenesis 21, 345-351.
52. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. (1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-467.
53. Hard, G. C., and Whysner, J. (1994). Risk assessment of d-limonene: an example of male rat-specific renal tumorigens. Crit. Rev. Toxicol. 24, 231-254.
54. Hart, R. W., Keenan, K., Turturro, A., Abdo, K. M., Leakey, J., and Lyn-Cook, B. (1995). Caloric restriction and toxicity. Fund. Appl. Toxicol. 25, 184-195.
55. Haseman, J. D., and Huff, J. E. (1987). Species correlation in long-term carcinogenicity studies. Cancer Lett. 34, 125-132.
56. Hein, D. W. (2006). N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649-1658.
57. Hennekens, C. H., Buring, J. E., Manson, J. E., Stampfer, M., Rosner, B., Cook, N. R., Belanger, C., LaMotte, F., Gaziano, J. M., Ridker, P. M., et al. (1996). Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 1145-1149.
58. Hill, A. B. (1965). The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295-300.
59. Hill, J. (1761). Cautions against the immoderate use of snuff. (R. Baldwin and J. Jackson, Eds.), London, UK.
60. Hill, R. N., Erdreich, L. S., Paynter, O. E., Roberts, P. A., Rosenthal, S. L., and Wilkinson, C. F. (1989). Thyroid follicular cell carcinogenesis. Fundam Appl. Toxicol. 12, 629-697.
61. Hoeijmakers, J. H. (2009). DNA damage, aging, and cancer. N. Engl. J. Med. 361, 1475-1485.
62. Hueper, W. C., Wiley, F. H., and Wolfe, H. D. (1938). Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. J. Ind. Hyg. Toxicol. 20, 46-84.
63. International Agency for Research on Cancer (IARC). (1999). Saccharin and its salts. Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances. IARC Monogr. Eval. Carcinog. Risks Hum. 73, 517-624.
64. IARC Working Group (IARC WG). (1999). Consensus report. International Agency for Research on Cancer. IARC Sci. Publ. 147, 1-32.
65. Ito, N., Tamano, S., and Shirai, T. (2003). A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals. Cancer Sci. 94, 3-8.
66. Kavlock, R., and Dix, D. (2010). Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk. J. Toxicol. Environ. Health B Crit. Rev. 13, 197-217.
67. Kennaway, E., and Hieger, I. (1930). Carcinogenic substances and their fluorescence spectra. Br. Med. J. 1, 1044-1046.
68. Kinosita, R. (1936). Research on the carcinogenesis of the various chemical substances. Gann 30, 423-426.
69. Kirkland, D., Pfuhler, S., Tweats, D., Aardema, M., Corvi, R., Darroudi, F., Elhajouji, A., Glatt, H., Hastwell, P., Hayashi, M., et al. (2007). How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM Workshop. Mutat. Res. 628, 31-55.
70. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., et al. (2003). PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33, 655-780.
71. Klein, G., and Klein, E. (1986). Conditioned tumorigenicity of activated oncogenes. Cancer Res. 46, 3211-3224.
72. Knudson, A. G. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 68, 820-823.
73. Knudson, A. G. (1993). Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U.S.A. 90, 10914-10921.
74. Kodama, M., and Kodama, T. (1998). Comparative epidemiology of cancers of the testis, lung, bladder and stomach with special reference to the possible implication of environmental hormones in the recent risk changes of the 4 neoplasia types. Int. J. Mol. Med. 2, 705-714.
75. Kripke, M. L., and Borsos, T. (1974). Editorial: Immune surveillance revisited. J. Natl. Cancer Inst 52, 1393-1395.
76. Kritchevsky, D. (1999). Caloric restriction and experimental carcinogenesis. Toxicol. Sci. 52(Suppl. 2), 13-16.
77. Lambert, I., Singer, T., Boucher, S. E., and Douglas, G. R. (2005). Detailed review of transgenic rodent mutation assays. Mutat. Res. 590, 1-280.
78. Lower, G. M., Jr., and Bryan, G. T. (1973). Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. Biochem. Pharmacol. 22, 1581-1588.
79. Lu, M. H., Hinson, W. G., Turturro, A., Sheldon, W. G., and Hart, R. W. (1993). Cell proliferation by cell cycle analysis in young and old dietary restricted mice. Mech. Ageing Dev. 68, 151-162.
80. Lutz, W. K., and Schlatter, J. (1992). Chemical carcinogens and overnutrition in diet-related cancer. Carcinogenesis 13, 2211-2216.
81. st century: a view from the pharmaceutical industry. Toxicol. Sci. 110, 40-46.
82. Marnett, L. J. (2009). The COXIB experience: a look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 49, 265-290.
83. Maronpot, R. R., Flake, G., and Huff, J. (2004). Relevance of animal carcinogenesis findings to human cancer predictions and prevention. Toxicol. Pathol. 32(Suppl. 1), 40-48.
84. McCann, J., Spingarn, N. E., Kobori, J., and Ames, B. N. (1975). Detection of carcinogens as mutagens: bacterial tester strains with R factor plasmids. Proc. Natl. Acad. Sci. U.S.A. 72, 979-983.
85. Meek, M. E., (Bette), Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., and Longfellow, D. G. (2003). Pastoor, T., Seed, J., and Patton, D. E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33, 591-653.
86. Miller, J. A., and Miller, E. C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In Origins of Human Cancer (H. H. Hiatt, Ed.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
87. Mitchell, S. C., and Smith, R. L. (2010). A physiological role for flavin-containing monooxygenase (FMO3) in humans? Xenobiotica 40, 301-305.
88. Moolgavkar, S. H., and Knudson, A. G. J. (1981). Mutation and cancer: a model for human carcinogenesis. J. Natl. Cancer Inst. 66, 1037-1052.
89. Munro, I. C., Ford, R. A., Kennepohl, E., and Sprenger, J. G. (1996). Correlation of structural class with no-observed-effect levels: a proposal for establishing a threshold of concern. Food Chem. Toxicol. 34, 829-867.
90. Murasaki, G., and Cohen, S. M. (1983). Co-carcinogenicity of sodium saccharin and N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide for the urinary bladder. Carcinogenesis 4, 97-99.
91. National Research Council (NRC). (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academies Press, Washington, DC.
92. Nie, A. Y., McMillian, M., Parker, J. B., Leone, A., Bryant, S., Yieh, L., Bittner, A., Nelson, J., Carmen, A., Wan, J., et al. (2006). Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45, 914-933.
93. Phillips, D. H., Farmer, P. B., Beland, F. A., Nath, R. G., Poirier, M. C., Reddy, M. V., and Turteltaub, K. W. (2000). Methods of DNA adduct determination and their application to testing compounds for genotoxicity. Environ. Mol. Mutagen. 35, 222-233.
94. Poirier, M. C., Beland, F. A., Deal, F. H., and Swenberg, J. A. (1989). DNA adduct formation and removal in specific liver cell populations during chronic dietary administration of 2-acetylaminofluorene. Carcinogenesis 10, 1143-1145.
95. Pott, P. (1775). Chirurgical Observations Relative to the Cataract. The Polypus of the Nose, the Cancer of the Scrotum, the Different Kinds of Ruptures, and the Mortification of the Toes and Feet. Chapter III. Hawes, W. Clarke, and R. Collins, London, UK. pp. 60-68.
96. Preston-Martin, S., Pike, M. C., Ross, R. K., Jones, P. A., and Henderson, B. E. (1990). Increased cell division as a cause of human cancer. Cancer Res. 50, 7415-7421.
97. Prichard, J. B., French, J. E., Davis, B. J., and Haseman, J. K. (2003). The role of transgenic mouse models in carcinogen identification. Environ. Health Perspec. 111, 444-454.
98. Rehn, L. (1895). Blasengeschwülste be: Fuchsin-arbeitern. Arch. Klin. Chir. 50, 588-600.
99. Ross, P. K., Woods, C. G., Bradford, B. U., Kosyk, O., Gatti, D. M., Cunningham, M. L., and Rusyn, I. (2009). Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liver. Toxicol. Appl. Pharmacol. 235, 199-207.
100. Rotroff, D. M., Wetmore, B. A., Dix, D. J., Ferguson, S. S., Clewell, H. J., Houck, K. A., LeCluyse, E. L., Andersen, M. E., Judson, R. S., Smith, C. M., et al. (2010). Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 117, 348-358.
101. Ruch, R. J., and Trosko, J. E. (2001). Gap-junction communication in chemical carcinogenesis. Drug Metab. Rev. 33, 117-121.
102. Schwartz, R. S. (1895). Another look at immunologic surveillance. N. Engl. J. Med. 293, 181-184.
103. Seed, J., Carney, E. W., Corley, R. A., Crofton, K. M., DeSesso, J. M., Foster, P. M. D., Kavlock, R., Kimmel, G., Klaunig, J., Meek, M. E., et al. (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev. Toxicol. 35, 663-672.
104. Seifried, H. E., Seifried, R. M., Clarke, J. J., Junghans, T. B., and San, R. H. (2006). A compilation of two decades of mutagenicity test results with the Ames Salmonella typhimurium and L5178Y mouse lymphoma cell mutation assays. Chem. Res. Toxicol. 19, 627-644.
105. Shin, A., Shrubsole, M. J., Rice, J. M., Cai, Q., Doll, M. A., Long, J., Smalley, W. E., Shyr, Y., Sinha, R., Ness, R. M., et al. (2008). Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol. Biomarkers Prev. 17, 320-329.
106. 01 study-overview. Fundam. Appl. Toxicol. 1, 28-63.
107. Sonich-Mullin, C., Fielder, R., Wiltse, J., Baetcke, K., Dempsey, J., Fenner-Crisp, P., Grant, D., Hartley, M., Knaap, A., Kroese, D., Mangelsdorf, I., Meek, E., Rice, J. M., and Younes, M. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 34, 146-152.
108. Tannenbaum, A. (1940). The initiation and growth of tumors. Introduction. Effects of undernutrition. Am. J. Cancer 38, 335-350.
109. Thomas, L. (1959). Discussion. In Cellular and Humoral Aspects of Hypersensitive States (H. S. Lawrence, Ed.), p. 529. Hoeber-Harper, New York, NY.
110. Thomas, R. S., Pluta, L., Yang, L., and Halsey, T. A. (2007). Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol. Sci. 97, 55-64.
111. Tong, W., Welsh, W. J., Shi, L., Fang, H., and Perkins, R. (2003). Structure-activity relationship approaches and applications. Environ. Toxicol. Chem. 22, 1680-1695.
112. Vajdic, C. M., McDonald, S. P., McCredie, M. R., van Leeuwen, M. T., Stewart, J. H., Law, M., Van Kaick, G., Wesch, H., Lührs, H., and Liebermann, D. (1986). Radiation-induced primary liver tumors in "thorotrast patients". Rec. Results Cancer Res. 100, 16-22.
113. Vastag, B. (2009). Nutrients for prevention: negative trials send researchers back to drawing board. J. Natl. Cancer Inst. 101, 446-448; 451.
114. Watanabe, S., Brown, C., and Young, J. (1986). Cumulative incidence rates for Hodgkin's disease and other hematologic malignancies, with special reference to age-related carcinogenesis. Jpn. J. Cancer Res. 77, 743-749.
115. Wattenberg, L. W. (1985). Chemoprevention of cancer. Cancer Res. 45, 1-8.
116. Weisburger, J. H., and Williams, G. M. (1981). Carcinogen testing: current problems and new approaches. Science 214, 401-407.
117. Whysner, J., Ross, P. M., and Williams, G. M. (1996). Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71, 153-191.
118. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (1996). Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71, 153-191.
119. Wu, W. K., Sung, J. J., Lee, C. W., Yu, J., and Cho, C. H. (2010). Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 295, 7-16.
120. Yamagiwa, K., and Ichikawa, K. (1915). Experimentelle studie über die pathogenese der Epithelialgeschwülste. Mitt. Med. Fak. Kaiserl Univ. Tokio 15, 295-344.
121. Yang, Q., Nagano, T., Shah, Y., Cheung, C., Ito, S., and Gonzalez, F. J. (2008). The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol. Sci. 101, 132-139.
122. Yoshida, T. (1933). Ü ber die serienweise Verfolgung der Veränderungen der Leber der experimentellen Hepatomerzeugung durch o-aminoazotuol. Trans. Jpn. Pathol. Soc. 23, 636-638.